Читать книгу The Peripheral T-Cell Lymphomas - Группа авторов - Страница 109

1 1 Alibert, J.L. (1806). Description des maladies de la peau observées a ‘hôpital Saint Louis et exposition des meilleures méthodes suivies pour leur traitement. Paris: Barrois L’Aine et Fils.

2 2 Sezary, A. and Bouvrain, Y. (1938). Erythrodermic avec presence de cellules monstrueuses dams le derme et le sang circulant. Bull Soc Fr Dermatol Syphiligr 45: 254–260.

3 3 Gerard‐Marchant, R., Hamlin, I., Lennert, K. et al. (1974). Classification of non‐Hodgkin lymphomas. Lancet 2: 406–408.

4 4 Whang‐Peng, J., Bunn, P.A. Jr., Knutsen, T. et al. (1982). Clinical implications of cytogenetic studies in cutaneous T‐cell lymphoma (CTCL). Cancer 50 (8): 1539–1553.

5 5 Pinkus, G.S., Said, J.W., and Hargreaves, H. (1979). Malignant lymphoma, T‐cell type A distinct morphologic variant with large multilobated nuclei, with a report of four cases. Am J Clin Pathol 72 (4): 540–550.

6 6 Harris, N.L., Jaffe, E.S., Stein, H. et al. (1994). A revised European‐American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (5): 1361–1392.

7 7 Satou, A.N., Bennani, N., and Feldman, A.L (2019). Update on the classification of T‐cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol 12 (10): 833–843.

8 8 Non‐Hodgkin’s Lymphoma Classification Project (1997). A clinical evaluation of the International Lymphoma Study Group classification of non‐Hodgkin’s lymphoma. Blood 89: 3909–3918.

9 9 Swerdlow, S.H., Campo, E., Harris, N.L. et al. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, (rev. 4e). Lyon: International Agency for Research on Cancer.

10 10 Vose, J., Armitage, J., and Weisenburger, D. (2008). International peripheral T‐cell and natural killer/T‐cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26 (25): 4124–4130.

11 11 Rüdiger, T., Weisenburger, D.D., Anderson, J.R. et al. (2002). Peripheral T‐cell lymphoma (excluding anaplastic large‐cell lymphoma): results from the Non‐Hodgkin’s Lymphoma Classification Project. Ann Oncol 13 (1): 140–149.

12 12 Bellei, M., Chiattone, C.S., Luminari, S. et al. (2012). T‐cell lymphomas in South America and Europe. Rev. Bras. Hematol. Hemoter. 34: 42–47.

13 13 National Cancer Institute. (2019). SEER Cancer Statistics Review (CSR) 1975–2016. https://seer.cancer.gov/archive/csr/1975_2016 (accessed 11 August 2020).

14 14 Armitage, J.O. and Weisenburger, D.D. (1998). New approach to classifying non‐Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non‐Hodgkin’s Lymphoma Classification Project. J Clin Oncol 16: 2780–2795.

15 15 Abramson, J.S., Feldman, T., Kroll‐Desrosiers, A.R. et al. (2014). Peripheral T‐cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 25: 2211–2217.

16 16 Ellin, F., Landström, J., Jerkeman, M., and Relander, T. (2014). Real‐world data on prognostic factors and treatment in peripheral T‐cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124: 1570–1577.

17 17 Abouyabis, A.N., Shenoy, P.J., Lechowicz, M.J., and Flowers, C.R. (2008). Incidence and outcomes of the peripheral T‐cell lymphoma subtypes in the United States. Leuk Lymphoma 49: 2099–2107.

18 18 Adams, S.V., Newcomb, P.A., and Shustov, A.R. (2016). Racial patterns of peripheral T‐cell lymphoma incidence and survival in the United States. J Clin Oncol 34: 963–971.

19 19 Weisenburger, D.D., Savage, K.J., Harris, N.L. et al. (2011). Peripheral T‐cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T‐cell Lymphoma Project. Blood 117: 3402–3408.

20 20 Wang, S.S., Flowers, C.R., Kadin, M.E. et al. (2014). Medical history, lifestyle, family history, and occupational risk factors for peripheral T‐cell lymphomas: the InterLymph Non‐Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014 (48): 66–75.

21 21 Cahoon, E.K., Pfeiffer, R.M., Wheeler, D.C. et al. (2015). Relationship between ambient ultraviolet radiation and non‐Hodgkin lymphoma subtypes: a U.S. population based study of racial and ethnic groups. Int J Cancer 136 (5): E432–E441.

22 22 Grogg, K.L., Attygalle, A.D., Macon, W.R. et al. (2005). Angioimmunoblastic T‐cell lymphoma: a neoplasm of germinal‐center T‐helper cells? Blood 106: 1501–1502.

23 23 Krenacs, L., Schaerli, P., Kis, G., and Bagdi, E. (2006). Phenotype of neoplastic cells in angioimmunoblastic T‐cell lymphoma is consistent with activated follicular B helper T cells. Blood 108: 1110–1111.

24 24 Rudiger, T., Weisenburger, D.D., Coiffier, B. et al. (2008). Angioimmunoblastic T‐cell lymphoma: a report from the international peripheral T‐cell lymphoma project. Ann Oncol 19 (Suppl 4): 119.

25 25 Morton, L.M., Wang, S.S., Devesa, S.S. et al. (2006). Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107: 265.

26 26 de Leval, L., Parrens, M., Le Bras, F. et al. (2015). Angioimmunoblastic T‐cell lymphoma is the most common T‐cell lymphoma in two distinct French information data sets. Haematologica 100 (9): e361–e364.

27 27 National Cancer Instutite. Surveillance, Epidemiology, and End Results (SEER) Program. http://www.seer.cancer.gov [updated based on the November 2013 submission] (accessed 11 August 2020).

28 28 Ohsaka, A., Saito, K., Sakai, T. et al. (1992). Clinicopathologic and therapeutic aspects of angioimmunoblastic lymphadenopathy‐related lesions. Cancer 69: 1259–1267.

29 29 Pautier, P., Devidas, A., Delmer, A. et al. (1999). Angioimmunoblastic‐like T‐cell non Hodgkin’s lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 32: 545–552.

30 30 Siegert, W., Nerl, C., Agthe, A. et al. (1995). Angioimmunoblastic lymphadenopathy (AILD)‐type T‐cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol 6: 659–664.

31 31 Federico, M., Rudiger, T., Bellei, M. et al. (2013). Clinicopathologic characteristics of angioimmunoblastic T‐cell lymphoma: analysis of the international peripheral T‐cell lymphoma project. J Clin Oncol 31: 240–246.

32 32 Khan, G., Norton, J.A., and Slavin, G. (1993). Epstein‐Barr virus in angioimmunoblastic T‐cell lymphomas. Histopathology 22 (2): 145–149.

33 33 Smith, A., Crouch, S., Lax, S. et al. (2015). Lymphoma incidence, survival and prevalence 2004‐2014: sub‐type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer 112 (9): 1575–1584.

34 34 Al‐Hamadani, M., Habermann, T.M., Cerhan, J.R. et al. (2015). Non‐Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol 90: 790–795.

35 35 Guru Murthy, G.S., Hamadani, M., Bhatt, V.R. et al. (2017). Systemic anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: a population‐based analysis of incidence and survival. Clin Lymphoma Myeloma Leuk 17: 201–206.

36 36 Savage, K.J., Harris, N.L., Vose, J.M. et al. (2008). ALK– anaplastic large‐cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T‐cell lymphoma, not otherwise specified: report from the International Peripheral T‐Cell Lymphoma Project. Blood 111: 5496–5504.

37 37 Falini, B., Pileri, S., Zinzani, P.L. et al. (1999). ALK+ lymphoma: clinico‐pathological findings and outcome. Blood 93: 2697–2706.

38 38 Fallah, M., Liu, X., Ji, J. et al. (2014). Autoimmune diseases associated with nonHodgkin lymphoma: a nationwide cohort study. Ann Oncol 25 (10): 2025–2030.

39 39 Herling, M., Rassidakis, G.Z., Jones, D. et al. (2004). Absence of Epstein‐Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria. Hum Pathol 35: 455–459.

40 40 Castillo, J.J., Beltran, B.E., Bibas, M. et al. (2011). Prognostic factors in patients with HIV‐associated peripheral T‐cell lymphoma: a multicenter study. Am J Hematol 86: 256–261.

41 41 Olack, B., Gupta, R., and Brooks, G.S. (2007). Anaplastic large cell lymphoma arising in a saline breast implant capsule after tissue expander breast reconstruction. Ann Plast Surg 59: 56–57.

42 42 Lazzeri, D., Agostini, T., Bocci, G. et al. (2011). ALK‐1‐negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. Clin Breast Cancer 11: 283–296.

43 43 de Jong, D., Vasmel, W.L., de Boer, J.P. et al. (2008). Anaplastic large‐cell lymphoma in women with breast implants. JAMA 300 (17): 2030–2035.

44 44 Brody, G.S., Deapen, D., Taylor, C.R. et al. (2015). Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg 135: 695–705.

45 45 Picard, F.J., Coulthart, M.B., Oger, J. et al. (1995). Human T‐lymphotropic virus type 1 in coastal natives of British Columbia: phylogenetic affinities and possible origins. J Virol 69: 7248–7256.

46 46 Hjelle, B., Khabbaz, R.F., Conway, G.A. et al. (1994). Prevalence of human T cell lymphotropic virus type II in American Indian populations of the southwestern United States. Am J Trop Med Hyg 51: 11–15.

47 47 Phillips, A.A., Shapira, I., Willim, R.D. et al. (2010). A critical analysis of prognostic factors in North American patients with human T‐cell lymphotropic virus type‐1‐associated adult T‐cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer 116: 3438–3446.

48 48 Laurini, J.A., Perry, A.M., Boilesen, E. et al. ((2012). Classification of non‐Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 120: 4795–4801.

49 49 Chihara, D., Ito, H., Matsuda, T. et al. (2014). Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164: 536–545.

50 50 Kawano, N., Yoshida, S., Kuriyama, T. et al. (2015). Clinical features and treatment outcomes of 81 patients with aggressive type adult T‐cellleukemia‐lymphoma report: single institution over a 7‐year period (2006‐2012). Intern Med 54 (12): 1489–1498.

51 51 Anh, P., Rachel, V., and Mary, J.L. (2016). T‐cell lymphoma epidemiology: the known and unknown. Curr Hematol Malig Rep 11: 492–503.

52 52 Iwanaga, M., Watanabe, T., and Yamaguchi, K. (2012). Adult T‐cell leukemia: review of epidemiological evidence. Front Microbiol 3: 322.

53 53 Koff, J.L., Chihara, D., Phan, A. et al. (2015). To each its own: linking the biology and epidemiology of NHL subtypes. Curr Hematol Malig Rep 10 (3): 244–255.

54 54 Yamamoto, J.F. and Goodman, M.T. (2008). Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002. Cancer Causes Control 19: 379–390.

55 55 Matutes, E. (2007). Adult T‐cell leukaemia/lymphoma. J Clin Pathol 60: 1373–1377.

56 56 Hanchard, B. (1996). Adult T‐cell leukemia/lymphoma in Jamaica: 1986–1995. J Acquir Immune Defic Syndr Hum Retrovirol 13 (Suppl 1)): S20–S25.

57 57 Yoshida, N. and Chihara, D. (2015). Incidence of adult T‐cell leukemia/ lymphoma in nonendemic areas. Curr Treat Options Oncol 16 (7): 1–8.

58 58 Jaffe, E.S., Chan, J.K., Su, I.J. et al. (1996). Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas: definitions, differential diagnosis, and epidemiology. Am J SurgPathol 20: 103–111.

59 59 Arber, D.A., Weiss, L.M., Albújar, P.F. et al. (1993). Nasal lymphomas in Peru. High incidence of T‐cell immunophenotype and Epstein–Barr virus infection. Am J Surg Pathol 17: 392–399.

60 60 Ai, W.Z., Chang, E.T., Fish, K. et al. (2012). Racial patterns of extranodal natural killer/T‐cell lymphoma, nasal type, in California: a population‐based study. Br J Haematol 156 (5): 626–632.

61 61 Au, W.Y., Weisenburger, D.D., Intragumtornchai, T. et al. (2009). Clinical differences between nasal and extranasal natural killer/T‐cell lymphoma: a study of 136 cases from the International Peripheral T‐Cell Lymphoma Project. Blood 113: 3931–3937.

62 62 Li, C.C., Tien, H.F., Tang, J.L. et al. (2004). Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T‐cell or T‐cell lymphoma. Cancer 100: 366–375.

63 63 Matutes, E., Brito‐Babapulle, V., Swansbury, J. et al. (1991). Clinical and laboratory features of 78 cases of T‐prolymphocytic leukemia. Blood 78: 3269–3274.

64 64 Herling, M., Khoury, J.D., Washington, L.T. et al. (2004). A systematic approach to diagnosis of mature T‐cell leukemias reveals heterogeneity among WHO categories. Blood 104: 328–335.

65 65 Melo, J.V., Catovsky, D., and Galton, D.A. (1986). The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 63: 377–387.

66 66 Jain, P., Aoki, E., Keating, M. et al. (2017). Characteristics, outcomes, prognostic factors and treatment of patients with T‐cell prolymphocytic leukemia (T‐PLL). Ann Oncol 28: 1554–1559.

67 67 Brito‐Babapulle, V. and Catovsky, D. (1991). Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T‐prolymphocytic leukemia and T‐cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet 55: 1–9.

68 68 Taylor, A.M., Metcalfe, J.A., Thick, J., and Mak, Y.F. (1996). Leukemia and lymphoma in ataxia telangiectasia. Blood 87: 423–438.

69 69 Shah, M.V., Hook, C.C., Call, T.G., and Go, R.S. (2016). A population‐based study of large granular lymphocyte leukemia. Blood Cancer J 6 (8): e455.

70 70 Boeckx, N., Uyttebroeck, A., Langerak, A.W. et al. (2004). Clonal proliferation of T‐cell large granular lymphocytes. Pediatr Blood Cancer 42: 275–277.

71 71 Bareau, B., Rey, J., Hamidou, M. et al. (2010). Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica 95: 1534–1541.

72 72 Goyal, T., Thakral, B., Wang, S.A. et al. (2018). T‐cell large granular lymphocytic leukemia and coexisting B‐cell lymphomas: a study from the bone marrow pathology group. Am J Clin Pathol 149: 164–171.

73 73 Dhodapkar, M.V., Li, C.Y., Lust, J.A. et al. (1994). Clinical spectrum of clonal proliferations of T‐large granular lymphocytes: a T‐cell clonopathy of undetermined significance? Blood 84: 1620–1627.

74 74 Jaffe, E.S. (2003). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer Press.

75 75 Toro, J.R., Liewehr, D.J., Pabby, N. et al. (2003). Gamma‐delta T‐cell phenotypeis associated with significantly decreased survival in cutaneous T‐cell lymphoma. Blood 101 (9): 3407–3412.

76 76 Tripodo, C., Iannitto, E., Florena, A.M. et al. (2009). Gamma‐delta T‐cell lymphomas. Nat Rev Clin Oncol 6 (12): 707–717.

77 77 de Baaij, L.R., Berkhof, J., van de Water, J.M.W. et al. (2015). A new and validated clinical prognostic model (EPI) for enteropathy‐associated T‐cell lymphoma. Clin Cancer Res 21 (13): 3013–3019.

78 78 Tse, E., Gill, H., Loong, F. et al. (2012). Type II enteropathy‐associated T‐cell lymphoma: a multicenter analysis from the Asia lymphoma study group. Am J Hematol 87 (7): 663–668.

79 79 Yabe, M., Miranda, R.N., and Medeiros, L.J. (2018). Hepatosplenic T‐cell lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. Hum Pathol 74: 5–16.

80 80 Belhadj, K., Reyes, F., Farcet, J.P. et al. (2003). Hepatosplenic gammadelta T‐cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 102 (13): 4261–4269.

81 81 Falchook, G.S., Vega, F., Dang, N.H. et al. (2009). Hepatosplenic gamma‐delta T‐cell lymphoma: clinicopathological features and treatment. Ann Oncol 20: 1080–1085.

82 82 Ross, C.W., Schnitzer, B., Sheldon, S. et al. (1994). Gamma/delta T‐cell posttransplantation lymphoproliferative disorder primarily in the spleen. Am J Clin Pathol 102: 310–315.

83 83 Burg, G. (2015). Systemic involvement in mycosis fungoides. Clin Dermatol 33 (5): 563–571.

84 84 Willemze, R. (2006). Primary cutaneous B‐cell lymphoma: classification and treatment. Curr Opin Oncol 18 (5): 425–431.

85 85 Scarisbrick, J.J., Kim, Y.H., Whittaker, S.J. et al. (2014). Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Br J Dermatol 170 (6): 1226–1236.

86 86 Tan, E.S., Tang, M.B., and Tan, S.H. (2006). Retrospective 5‐year review of 131 patients with mycosis fungoides and Sézary syndrome seen at the National Skin Centre, Singapore. Australas J Dermatol 47 (4): 248–252.

87 87 Morales Suãrez‐Varela, M.M., Olsen, J., Kaerlev, L. et al. (2001). Are alcohol intake and smoking associated with mycosis fungoides? A European multicentre case‐control study. Eur J Cancer 37 (3): 392–397.

88 88 Aschebrook‐Kilfoy, B., Cocco, P., La Vecchia, C. et al. (2014). Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sezary syndrome: the InterLymph non‐Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr 2014 (48): 98–105.

89 89 Criscione, V.D. and Weinstock, M.A. ((2007). IncidenceofcutaneousT‐celllymphoma in the United States, 1973–2002. Arch Dermatol 143 (7): 854–859.

90 90 Desai, M., Liu, S., and Parker, S. (2015). Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sezary syndrome in the southeastern United States: a single‐institution cohort. J Am Acad Dermatol 72 (2): 276–285.